Table 2.
CD4-validated TCR-recognizing RAS hotspot mutation, available for allogeneic treatment.
| RAS mutation | # TCRs discovered | HLA-II restriction | % of individuals that have the allele (Allele Frequency) | % Patients eligible for treatment | Patient number | Method | Cancer diagnosis | References |
|---|---|---|---|---|---|---|---|---|
| KRAS p.G12D (35%) | 6 | DRB3*02 | 32% (*16.6% U.S. San Francisco Caucasian) | 11.2 | 4238 | PBL IVS | Colon | 41, 51 |
| KRAS p.G12V (24%) | 1 | DRB1*07:01 | 25.5% (14.5%) | 6.12 | 4148 | TIL screening | Endometrial | 52 |
| 1 | DPB1*03:01 | 20% (10%) | 4.8 | 4360 | PBL IVS | Colon | ||
| 1 | DRB1*01:01 | 18% (9%) | 4.32 | 4304 | TIL screening | Colon | ||
| KRAS p.G13D (13%) | 2 | DQA1*05:01/DQB1*03:01 | 35.1% (19.1%) | 4.55 | 4400 | TIL screening | Colon | |
| KRAS p.G12R (3%) | 1 | DQA1*05:05(05:01)/DQB1*03:01 | 35.1% (19.1%) | 1.05 | 4268 | TIL screening | Colon | |
| 1 | DRB5*01 | 35% (*18% U.S. San Francisco Caucasian) | 1.05 | 4270 | TIL screening | Pancreatic | ||
| 33.09 |
Note: CD4 TCR Supplementary table showing columns (from left to right): the hotspot mutation recognized by the TCR and the percentage of this mutation among RAS-mutated cancer patients; number of TCRs discovered from the same patient recognizing the same target; the HLA-II restriction each TCR recognizes; percentage of the allele frequency (taken from allelefrequencies.net) and calculation of the percentage of the individuals in the Caucasian or subpopulations (*); percentage of patients eligible for treatment, calculated by multiplying the frequency of individuals that have the allele with the frequency of this RAS mutation (as in the first column) with the sum of percentages from all TCRs (the bottom of this column); patient number; the method used to find the TCR (TIL screen/PBL IVS); patient cancer diagnosis in which TCR was found; reference if the TCR has been published before and, if so, where.